Home » GSK Partners with Canadian Biotech Medicago on COVID-19 Vaccine
GSK Partners with Canadian Biotech Medicago on COVID-19 Vaccine
GlaxoSmithKline (GSK) has teamed up with Canadian biotech company Medicago to develop a COVID-19 vaccine.
The companies plan to launch a phase 1 clinical trial of the vaccine this month.
Medicago will contribute virus-like particles (VLPs) produced through recombinant DNA technology that stimulate an immune response to the coronavirus, and GSK will supply an adjuvant to boost the response.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May